SCHEMBL12876130

SCHEMBL12876130

Cc1cc(/C=C\c2cccnc2)cc(-c2csc(Cn3cc(C(=O)O)cn3)n2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
ALOX15 P16050 1/20 0.37
ADORA3 P0DMS8 2/20 0.37
ADORA1 P30542 2/20 0.37
GRM5 P41594 1/20 0.36
DNM1L O00429 1/20 0.36
ALOX5 P09917 1/20 0.35
PTGS1 P23219 1/20 0.35
PTGS2 P35354 1/20 0.35
CYP1A1 P04798 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP1B1 Q16678 1/20 0.35
NAMPT P43490 2/20 0.35
AKT1 P31749 1/20 0.35
KLKB1 P03952 2/20 0.34
SIRT5 Q9NXA8 1/20 0.34
GRM1 Q13255 1/20 0.34
CHRM5 P08912 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12876132 0.90 L3MBTL1 (0.38) KMT2ANPC1RAB9AALOX15ADORA3
SCHEMBL1198930 0.88 ALDH1A1 (0.39) KMT2ANPC1RAB9AALOX15CYP1A1
SCHEMBL1198931 0.88 ALDH1A1 (0.39) KMT2ANPC1RAB9AALOX15CYP1A1
SCHEMBL12876201 0.85 KLKB1 (0.40) KMT2ANPC1RAB9AALOX15DNM1L
SCHEMBL12876187 0.83 GRM5 (0.38) KMT2ANPC1RAB9AALOX15ADORA3
SCHEMBL12875974 0.83 L3MBTL1 (0.41) KMT2ANPC1RAB9AADORA3AKT1
SCHEMBL12876129 0.81 KMT2A (0.45) KMT2AGRM5KLKB1
SCHEMBL1197723 0.81 HDAC3 (0.43) KMT2ANPC1RAB9AKLKB1LMNA
SCHEMBL1197722 0.81 HDAC3 (0.43) KMT2ANPC1RAB9AKLKB1LMNA
SCHEMBL1198415 0.81 KDM4E (0.37) KMT2ACYP1A2NAMPTAKT1SIRT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A KMT2A 3197/4885NPC1 3877/4885RAB9A 2507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.